Literature DB >> 15681944

Hemodynamic changes after protamine administration: association with mortality after coronary artery bypass surgery.

Ian J Welsby1, Mark F Newman, Barbara Phillips-Bute, Robert H Messier, Emil D Kakkis, Mark Stafford-Smith.   

Abstract

BACKGROUND: Protamine sulfate is standard therapy to reverse heparin anticoagulation. Hemodynamic responses to protamine are common, ranging from minor perturbations to cardiovascular collapse. Although severe fatal reactions occur, the relation of less extreme responses with postoperative mortality is unknown. Therefore, the authors tested the hypothesis that hemodynamic "protamine reactions" (systemic hypotension and pulmonary hypertension) are associated with mortality after cardiac surgery.
METHODS: In a university hospital setting, the authors studied 6,921 coronary bypass patients using automated anesthesia record-keeping data and quality assurance databases. Degree/duration integrals of systemic hypotension (< 100 mmHg) and pulmonary hypertension (> 30 mmHg) for the 30-min after protamine administration were assessed for linear associations with mortality using multiple logistic regression models adjusting for risk factors.
RESULTS: Overall mortality was 2%; greater hemodynamic responses were associated with increased mortality by odds ratios of 1.28 (systemic hypotension: 95% confidence interval, 1.14-1.43; P < 0.001) and 1.27 (pulmonary hypertension: 95% confidence interval, 1.06-1.48; P < 0.001) per 150-mmHg . min increment. Proximity of the response to protamine administration strengthened the relation, which persisted after exclusion of major hemodynamic disturbances. Tests for linearity confirmed an association even at the lowest range of values for both pressure effects.
CONCLUSIONS: Hemodynamic perturbations after protamine administration are independently related to in-hospital mortality after primary coronary artery bypass surgery; the relation is present even in the lowest observed range of values for both systemic hypotension and pulmonary hypertension. Although randomized trials are necessary to address causality, this evidence suggests that strategies that avoid or attenuate these reactions may improve patient care.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15681944     DOI: 10.1097/00000542-200502000-00011

Source DB:  PubMed          Journal:  Anesthesiology        ISSN: 0003-3022            Impact factor:   7.892


  14 in total

1.  Cardioprotection by resveratrol: a review of effects/targets in cultured cells and animal tissues.

Authors:  Joseph M Wu; Tze-Chen Hsieh; Zhirong Wang
Journal:  Am J Cardiovasc Dis       Date:  2011-04-27

2.  Engineered virus-like nanoparticles reverse heparin anticoagulation more consistently than protamine in plasma from heparin-treated patients.

Authors:  Andrew J Gale; Darlene J Elias; Patricia M Averell; Paul S Teirstein; Mitchell Buck; Steven D Brown; Zinaida Polonskaya; Andrew K Udit; M G Finn
Journal:  Thromb Res       Date:  2011-04-14       Impact factor: 3.944

Review 3.  Current periprocedural anticoagulation in transcatheter aortic valve replacement: could bivalirudin be an option? Rationale and design of the BRAVO 2/3 studies.

Authors:  Ziad Sergie; Thierry Lefèvre; Eric Van Belle; Socrates Kakoulides; Usman Baber; Efthymios N Deliargyris; Roxana Mehran; Eberhard Grube; Jochen Reinöhl; George D Dangas
Journal:  J Thromb Thrombolysis       Date:  2013-05       Impact factor: 2.300

4.  Heparin modifies the immunogenicity of positively charged proteins.

Authors:  Shalini L Chudasama; Benjamin Espinasse; Fred Hwang; Rui Qi; Manali Joglekar; Galyna Afonina; Mark R Wiesner; Ian J Welsby; Thomas L Ortel; Gowthami M Arepally
Journal:  Blood       Date:  2010-09-17       Impact factor: 22.113

5.  STS/SCA/AmSECT Clinical Practice Guidelines: Anticoagulation during Cardiopulmonary Bypass.

Authors:  Linda Shore-Lesserson; Robert A Baker; Victor Ferraris; Philip E Greilich; David Fitzgerald; Philip Roman; John Hammon
Journal:  J Extra Corpor Technol       Date:  2018-03

6.  High incidence of antibodies to protamine and protamine/heparin complexes in patients undergoing cardiopulmonary bypass.

Authors:  Grace M Lee; Ian J Welsby; Barbara Phillips-Bute; Thomas L Ortel; Gowthami M Arepally
Journal:  Blood       Date:  2013-02-19       Impact factor: 22.113

7.  Protamine reduces bleeding complications associated with carotid endarterectomy without increasing the risk of stroke.

Authors:  David H Stone; Brian W Nolan; Andres Schanzer; Philip P Goodney; Robert A Cambria; Donald S Likosky; Daniel B Walsh; Jack L Cronenwett
Journal:  J Vasc Surg       Date:  2010-01-04       Impact factor: 4.268

8.  Development of universal antidotes to control aptamer activity.

Authors:  Sabah Oney; Ruby T S Lam; Kristin M Bompiani; Charlene M Blake; George Quick; Jeremy D Heidel; Joanna Yi-Ching Liu; Brendan C Mack; Mark E Davis; Kam W Leong; Bruce A Sullenger
Journal:  Nat Med       Date:  2009-10-04       Impact factor: 53.440

9.  Less is more: We are administering too much protamine in cardiac surgery.

Authors:  Francesco De Simone; Pasquale Nardelli; Margherita Licheri; Giovanna Frau; Martina Baiardo Redaelli; Fabrizio Monaco; Alberto Zangrillo; Giovanni Landoni
Journal:  Ann Card Anaesth       Date:  2021 Apr-Jun

10.  Administration of Protamine Through Radial Arterial Access: A Prospective Observational Study.

Authors:  Priyanka Goyal; Sandeep Joshi; Monish S Raut
Journal:  Heart Views       Date:  2021-04-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.